Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

Science

Volumn 317, Issue 5835, 2007, Pages 239-242

  Miled, Nabil ^a,e   Yan, Ying ^b   Hon, Wai Ching ^a   Perisic, Olga ^a   Zvelebil, Marketa ^c   Inbar, Yuval ^d   Schneidman Duhovny, Dina ^d   Wolfson, Haim J ^d   Backer, Jonathan M ^b   Williams, Roger L ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d TEL AVIV UNIVERSITY   (Israel)

^e UNIVERSITY OF SFAX   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SH2;

CANCER; CRYSTALLOGRAPHY; ENZYME; MUTATION; PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CRYSTALLOGRAPHY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CATALYTIC DOMAIN; CATTLE; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SRC HOMOLOGY DOMAINS;

EID: 34447503808     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1135394     Document Type: Article

References (32)

1. L. C. Cantley, Science 296, 1655 (2002).
2. B. Vanhaesebroeck et al., Annu. Rev. Biochem. 70, 535 (2001).
3. M. P. Wymann, M. Zvelebil, M. Laffargue, Trends Pharmacol. Sci. 24, 366 (2003).
4. J. Luo, B. D. Manning, L. C. Cantley, Cancer Cell 4, 257 (2003).
5. L. H. Saal et al., Cancer Res. 65, 2554 (2005).
6. R. Wetzker, C. Rommel, Curr. Pharm. Des. 10, 1915 (2004).
7. M. P. Wymann, R. Marone, Curr. Opin. Cell Biol. 17, 141 (2005).
8. P. Workman, Biochem. Soc. Trans. 32, 393 (2004).
9. B. Geering, P. R. Cutillas, G. Nock, S. I. Gharbi, B. Vanhaesebroeck, Proc. Natl. Acad. Sci. U.S.A. 104, 7809 (2007).
10. J. Yu et al., Mot. Cell. Biol. 18, 1379 (1998).
11. K. Okkenhaug, B. Vanhaesebroeck, Sci. STKE 2001, pe1 (2001).
12. C. Jimenez, C. Hernandez, B. Pimentel, A. C. Carrera, J. Biol. Chem. 277, 41556 (2002).
13. C. L. Carpenter et al., J. Biol. Chem. 268, 9478 (1993).
14. R. Dhand et al., EMBO J. 13, 511 (1994).
15. J. Yu, C. Wjasow, J. M. Backer, J. Biol. Chem. 273, 30199 (1998).
16. Y. Samuels et al., Science 304, 554 (2004).
17. A. G. Bader, S. Kang, L. Zhao, P. K. Vogt, Nat. Rev. Cancer 5, 921 (2005).
18. S. Kang, A. G. Bader, P. K. Vogt, Proc. Natl. Acad. Sci. U.S.A. 102, 802 (2005).
19. T. Ikenoue et al., Cancer Res. 65, 4562 (2005).
20. S. J. Isakoff et al., Cancer Res. 65, 10992 (2005).
21. M. Gymnopoulos, M. A. Elsliger, P. K. Vogt, Proc. Natl. Acad. Sci. U.S.A. 104, 5569 (2007).
22. L. Stephens, R. Williams, P. Hawkins, Curr. Opin. Pharmacol. 5, 357 (2005).
23. L. Pirola et al., J. Biol. Chem. 276, 21544 (2001).
24. E. H. Walker, O. Perisic, C. Ried, L. Stephens, R. L. Williams, Nature 402, 313 (1999).
25. Materials and methods are available as supporting material on Science Online.
26. Z. Fu, E. Aronoff-Spencer, J. M. Backer, G. J. Gerfen, Proc. Natl. Acad. Sci. U.S.A. 100, 3275 (2003).
27. W. Elis, E. Lessmann, AA. Oelgeschlager, M. Huber, Biol. Chem. 387, 1567 (2006).
28. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
29. M. Landau et al., Nucleic Acids Res. 33, W299 (2005).
30. S. C. Shekar et al., J. Biol. Chem. 280, 27850 (2005).
31. R. T. Nolte, M. J. Eck, J. Schlessinger, S. E. Shoelson, S. C. Harrison, Nat. Struct. Biol. 3, 364 (1996).
32. We thank M. Waterfield and B. Vanhaesebroeck for the p110α plasmid, A. McCarthy for help at European Synchrotron Radiation Facility beamline ID14-4, and M. Girvin and G. Gerfen for helpful discussions. The work was supported by AstraZeneca (R.L.W.), Medical Research Council (R.L.W.), and NIH GM55692 (J.M.B.).